Mirum Pharmaceuticals, Inc.
MIRM
$102.19
-$9.21-8.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 50.19% | 54.74% | 53.66% | 62.33% | 69.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.19% | 54.74% | 53.66% | 62.33% | 69.31% |
| Cost of Revenue | 22.11% | 22.78% | 12.96% | 22.81% | 44.98% |
| Gross Profit | 58.53% | 64.97% | 68.97% | 77.49% | 78.19% |
| SG&A Expenses | 37.97% | 27.10% | 25.14% | 28.62% | 32.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.98% | 26.84% | 26.20% | 29.08% | 35.52% |
| Operating Income | 1.69% | 80.44% | 61.66% | 51.97% | 34.25% |
| Income Before Tax | -950.60% | 75.35% | 58.33% | 46.61% | 51.70% |
| Income Tax Expenses | -3.69% | 87.96% | -67.61% | -30.64% | 1.49% |
| Earnings from Continuing Operations | -932.90% | 73.43% | 58.50% | 46.35% | 51.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -932.90% | 73.43% | 58.50% | 46.35% | 51.22% |
| EBIT | 1.69% | 80.44% | 61.66% | 51.97% | 34.25% |
| EBITDA | 4.76% | 111.11% | 82.76% | 68.61% | 49.31% |
| EPS Basic | -739.41% | 74.46% | 61.38% | 51.46% | 58.75% |
| Normalized Basic EPS | 16.00% | 81.85% | 24.56% | 14.01% | -5.85% |
| EPS Diluted | -739.34% | 73.60% | 61.14% | 51.43% | 58.72% |
| Normalized Diluted EPS | 15.62% | 81.54% | 23.98% | 14.01% | -5.85% |
| Average Basic Shares Outstanding | 9.40% | 5.27% | 7.63% | 10.09% | 14.62% |
| Average Diluted Shares Outstanding | 12.72% | 8.62% | 11.10% | 10.09% | 14.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |